Intravitreal Injection of Triamcinolone Acetonide for Macular Edema : Long-term Safety and Efficacy after Two Years

Jae Ho Shin; Seung Won Lee; Do Kyun Kim; Dae Young Lee; Seung Young Yu; Hyung Woo Kwak

doi:10.3341/jkos.2007.48.12.1670

Journal List > J Korean Ophthalmol Soc > v.48(12) > 1007988

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Shin, Lee, Kim, Lee, Yu, and Kwak: Intravitreal Injection of Triamcinolone Acetonide for Macular Edema : Long-term Safety and Efficacy after Two Years

Original Article

J Korean Ophthalmol Soc 2007;48(12):1670-1674.

Published online: 30 August 2007

DOI: https://doi.org/10.3341/jkos.2007.48.12.1670

Intravitreal Injection of Triamcinolone Acetonide for Macular Edema : Long-term Safety and Efficacy after Two Years

Jae Ho Shin, M.D.¹, Seung Won Lee, M.D.², Do Kyun Kim, M.D.³, Dae Young Lee, M.D.⁴, Seung Young Yu, M.D., Ph.D.², Hyung Woo Kwak, M.D., Ph.D.^2,

¹Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea

²Department of Ophthalmology, KyungHee University College of Medicine, Seoul, Korea

³Department of Ophthalmology, KwanDong University College of Medicine, Seoul, Korea

⁴Department of Ophthalmology, Gachon University Gill Medical Center, Inchon, Korea

Address reprint requests to Hyung Woo Kwak, M.D., Ph.D., Department of Ophthalmology, KyungHee University College of Medicine, #1 Hoegi-dong, Dongdaemun-gu, Seoul 130-702, Korea Tel: 82-2-958-8451, Fax: 82-2-966-7340, E-mail: pbloadsky@naver.com

Received 7 March 2007 Accepted 24 July 2007

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To evaluate the 2 year safety and efficacy of intravitreal injection of triamcinolone acetonide in macular edema associated with diabetic retinopathy and retinal vein occlusion.

Methods

Medical records of patients who underwent an intravitreal injection of 4 milligrams of triamcinolone acetonide for macular edema due to diabetic retinopathy and retinal vein occlusion from September 2002 to March 2004 were reviewed retrospectively. Out of 108 eyes, 50 eyes, which allowed for continuous follow-up, were chosen. The measured results included visual acuity (ETDRS), macular thickness (OCT), intraocular pressure, formation or progression of cataract, and additional intervention.

Results

Out of 50 eyes, 17 eyes (34%) showed steady improvement of visual acuity and macular thickness in during the follow up period. Out of 17 eyes, 15 eyes underwent additional laser photocoagulation before or after injection. Significant elevation of IOP developed in 5 eyes (10%). Cataract progressed in 7 phakic eyes (14%) required operation.

Conclusions

Additional treatments such as laser photocoagualtion appear to enhance the duration of efficacy in intrvitreal triamcinolone for macular edema.

Keywords: Intavitreal triamcinolone acetonide, Macular edema

References

1. Sobrin L, D'Amico DJ. Controversies in intravitreal triamcinolone acetonide use. Int Ophthalmol Clin. 2005; 45:133–41.

2. Jonas JB, Martus P, Degenring RF, et al. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol. 2005; 123:1338–43.

3. Beer PM, Bakri SI, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003; 110:681–6.

4. Chieh JJ, Roth DB, Liu M, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina. 2005; 25:828–34.

5. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2005; 25:851–5.

6. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res. 2005; 24:587–611.

7. Lee J, Lee JH. The effect of intravitreal triamcinolone acetonide on cystoid macular edema. J Korean Ophthalmol Soc. 2004; 45:413–8.

8. Jonas JB, Degenring RF, Kamppeter BA, et al. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema. Am J Ophthalmol. 2004; 138:158–60.

9. Early treatment diabetic retinopathy study research group. Early photocoagulation for diabetic retinopathy. Ophthalmology. 1991; 98:766–85.

10. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging. 2003; 34:386–90.

11. Jonas JB. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular disease. Acta Ophthalmol Scand. 2005; 83:645–63.

12. Jonas JB, Degenring R, Kreissig I, Akkoyun I. Safety of intravitreal high-dose reinjection of triamcinolone acetonide. Am J Ophthalmol. 2004; 138:1054–5.

13. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004; 122:336–40.

Figure 1.

The changes in visual acuity 3, 6, and 24 months after IVTA.

Figure 2.

The changes in foveal thickness 3, 6, and 24 months after IVTA.

Figure 3.

The changes in IOP after IVTA.

TOOLS

Similar articles